Clinical trial of adjuvant chemotherapy with mFOLFOX6 (L-OHP+l-LV/5-FU)/XELOX(L-OHP+Capecitabine)after curative resection for stage III colon cancer
- Conditions
- Colon cancer
- Registration Number
- JPRN-UMIN000005427
- Lead Sponsor
- Saitama Medical Center,Saitama Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 130
Not provided
1.Synchronous multiple cancer and metachronous multiple cancer within 5-years. 2.Severe postoperative complications ,such as infection, ruptured suture, gastrointestinal bleeding. 3.Sensory peripheral neuropathy. 4.Uncontrolled hypertension. 5.Uncontrolled Diabetes Mellitus. 6.Marked abnormality of ECG, or clinically important cardiac disorders such as congestive heart failure, symptomatic coronary artery disease, uncontrolled arrythmia,history of cardiac infarction within 12 months. 7.Severe pulmonary complications, such as interstitial pneumonitis, pulmonary fibrosis, pulmonary emphysema. 8.With Evidence or history of psychiatric disability and central neurological disorder. 9.Diarrhea. 10.Systemic continuous administration of steroid drugs(p.o. or i.v.). 11.Pregnant, woman of child-bearing potential or lactating woman. 12.Not appropriate for the study at the physician's assessment.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method